Browsing Tag
antibody-drug conjugates
13 posts
Can Mycenax’s ADC linker license deal with RIN boost Taiwan’s global CDMO standing?
Find out how Mycenax Biotech Inc. is reshaping Taiwan’s ADC CDMO positioning through a global linker technology license deal with Japan’s RIN Institute.
Can Piramal Pharma Solutions’ ADCelerate platform gain an edge with IntoCell’s linker-payload tech?
Piramal Pharma Solutions teams up with IntoCell to expand ADCelerate platform and access cutting-edge linker-payload tech. Explore how this reshapes the CDMO landscape.
Half of platinum-resistant ovarian cancer patients respond to Raludotatug deruxtecan in REJOICE-Ovarian01 trial
Find out how Raludotatug deruxtecan achieved a 50 % response rate in platinum-resistant ovarian cancer and what it means for future ADC therapies.
AstraZeneca strikes $50bn U.S. deal to lower drug prices while reshoring manufacturing amid tariff freeze
AstraZeneca inks $50B U.S. deal to cut drug prices and boost onshore manufacturing. See what this means for patients, profits, and pharma’s policy future.
Can ifinatamab deruxtecan redefine treatment for late-stage small cell lung cancer? Here’s what the trial shows
Discover how ifinatamab deruxtecan delivered a 48% objective response rate in pretreated ES-SCLC. Read on for trial results and next steps.
BioNTech stock jumps 8.66% after DB-1303 meets primary endpoint in breast cancer trial
BioNTech stock surged after DB-1303 met its Phase 3 endpoint in HER2-positive breast cancer. Find out what this means for global oncology strategy.
Can Avacta’s peptide drug conjugates rival ADCs? The next chapter in targeted cancer delivery
Avacta’s peptide drug conjugates could change how we deliver cancer drugs. Find out how they compare to ADCs and what’s next for the UK biotech’s platform.
Piramal Pharma Solutions launches $90m U.S. expansion to boost sterile injectables and ADC manufacturing
Piramal Pharma Solutions invests $90 million to expand sterile injectables and ADC production in the U.S., positioning itself for major growth.
Dishman Carbogen Amcis (NSE: DCAL) to expand ADC manufacturing in Switzerland
Dishman Carbogen Amcis expands Swiss ADC manufacturing with CHF 25M co-investment. Learn how this aligns with its global CDMO strategy.
Mersana Therapeutics reports positive phase 1 data for novel ADC in triple-negative breast cancer
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical innovator, has announced promising early clinical data from its Phase 1 trial…